SABR to Oligoprogressive Lesions Delays Systemic Therapy Change in ER+ Advanced Breast Cancer
Administration of stereotactic ablative body radiotherapy to oligoprogressive lesions delayed a change in systemic therapy in patients with estrogen receptor–positive/HER2-negative breast cancer enrolled to the prospective phase 2 AVATAR trial.
Daily Adaptive Radiotherapy Delivers Improved Efficacy and Safety Outcomes in HNSCC
October 4th 2023Daily adaptive radiotherapy with 1-mm planning target volume margins is feasible in patients with head and neck squamous cell carcinoma and was associated with improved dosimetric parameters compared with standard radiotherapy.
Dr Wong on Hypofractionation vs Conventional Fractionation in Breast Cancer Postmastectomy
October 3rd 2023Julia S. Wong, MD, discusses findings from data presented on patient-reported toxicity results from the randomized trial of fractionation following breast reconstruction in patients with breast cancer.
Patients with breast cancer who received hypofractionated postmastectomy radiotherapy experienced similar toxicities vs those who received conventionally fractionated postmastectomy radiotherapy, according to a presentation shared at the 2023 American Society for Radiation Oncology Annual Meeting.
Dr Hoppe on Outcomes of the CheckMate 744 Trial in Hodgkin Lymphoma
October 2nd 2023Bradford (Brad) S. Hoppe, MD, MPH, discusses the rationale for investigating consolidative radiotherapy in place of autologous stem cell transplant in patients with low-risk, relapsed/refractory classic Hodgkin lymphoma who have been previously treated with nivolumab plus brentuximab vedotin, as investigated in the phase 2 CheckMate 744 study, as well as key findings from this trial.
Intensified Radiotherapy Emerging as New Standard
October 26th 2016Radiation therapy can be effectively delivered in more focused, intensive, and shorter-course treatment regimens that offer patients at least equivalent—and in some cases superior—outcomes in several tumor types, thus helping to mitigate challenging adverse effects of standard approaches.
Dr. Iyengar on the Rationale Behind Hypofractionated Radiation in NSCLC
October 18th 2016Puneeth Iyengar, MD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the rationale behind the use of hypofractionated radiation as a treatment for patients with non–small cell lung cancer.
Computer Simulation Helps Plan Transducer Placement in Glioblastoma
October 13th 2016For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields and employing a personalized transducer array, delivered electric field intensities that exceeded therapeutic intensities in 3 different tumor locations. The findings may aid treatment planning when using the NovoTAL System, which optimizes therapeutic delivery in 2 orthogonal directions to the gross tumor volume and proximal peri-tumoral brain zone.
Minimal Toxicities Reported in Extreme Hypofractionated Comparison Trial in Prostate Cancer
October 10th 2016Men with intermediate prostate cancer who received extreme hypofractionated radiotherapy reported a low incidence of side effects, with no significant differences compared with a similar cohort of men who received conventional fractionation after 2 years of treatment.
Radiation and TGFβ Inhibition Combo Elicits Activity in Metastatic Breast Cancer
A strategy to stimulate an immune response in radiation-damaged tumor cells resulted in preliminary evidence of activity—including longer survival—in a small clinical trial of patients with metastatic breast cancer.
No Benefit Observed From Combined Irradiation in Intermediate-Risk Prostate Cancer
The addition of external-beam radiotherapy to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease.
H-RT Reduces Treatment Time by One-Third in Low-Risk Prostate Cancer
October 5th 2016Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.